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Recent studies reveal many biomaterial vaccine carriers are able to activate immunostimulatory path-
ways, even in the absence of other immune signals. How the changing properties of polymers during
biodegradation impact this intrinsic immunogenicity is not well studied, yet this information could con-
tribute to rational design of degradable vaccine carriers that help direct immune response. We use
degradable poly(beta-amino esters) (PBAEs) to explore intrinsic immunogenicity as a function of the
degree of polymer degradation and polymer form (e.g., soluble, particles). PBAE particles condensed by
electrostatic interaction to mimic a common vaccine approach strongly activate dendritic cells, drive
antigen presentation, and enhance T cell proliferation in the presence of antigen. Polymer molecular
weight strongly influences these effects, with maximum stimulation at short degradation times – corre-
sponding to high molecular weight – and waning levels as degradation continues. In contrast, free poly-
mer is immunologically inert. In mice, PBAE particles increase the numbers and activation state of cells in
lymph nodes. Mechanistic studies reveal that this evolving immunogenicity occurs as the physicochem-
ical properties and concentration of particles change during polymer degradation. This work confirms the
immunological profile of degradable, synthetic polymers can evolve over time and creates an opportunity
to leverage this feature in new vaccines.
Statement of Significance
Degradable polymers are increasingly important in vaccination, but how the inherent immunogenicity of
polymers changes during degradation is poorly understood. Using common rapidly-degradable vaccine
carriers, we show that the activation of immune cells – even in the absence of other adjuvants – depends
on polymer form (e.g., free, particulate) and the extent of degradation. These changing characteristics
alter the physicochemical properties (e.g., charge, size, molecular weight) of polymer particles, driving
changes in immunogenicity. Our results are important as many common biomaterials (e.g., PLGA) are
now known to exhibit immune activity that alters how vaccines are processed. Thus, the results of this
study could contribute to more rational design of biomaterial carriers that also actively direct the prop-
erties of responses generated by vaccines.
 2015 Acta Materialia Inc. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Biomaterials have become important components in many
emerging vaccine and immunotherapy strategies. These materials
provide cargo protection, controlled release of antigens or immunesignals, and targeting of immune cells and secondary lymphoid
organs such as lymph nodes (LNs) – key tissues that help coordi-
nate immune function [1–3]. Intriguingly, several recent studies
demonstrate that poly(lactic-co-glycolic acid) (PLGA), polystyrene,
chitosan, and other polymers ubiquitous in the biomedical field
exhibit intrinsic immunostimulatory properties, even in the
absence of antigens, adjuvants, or other immune signals [1,4–9].
Pattern recognition receptors (PRRs) of the innate immune system
have the ability to recognize pathogen-associated and danger-
associated patterns through Toll-like receptor (TLR) and
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domain-like receptors, Rig-like helicases) [10]. These pathways
drive production of pro-inflammatory caspases and cytokines that
many polymers such as PLGA or polystyrene are able to activate.
For example, when dendritic cells (DCs) are treated with PLGA or
non-degradable polystyrene particles and a TLR agonist (TLRa),
these particles cause an increase in expression of surface activation
markers (e.g., CD40, CD80, CD86) [6,7,9]. Many of these important
polymers also increase inflammatory cytokines such as IL-1b, a key
mediator of the inflammasome that supports early immune
responses [6,7,10]. Several studies have investigated the link
between these types of inflammatory/immunostimulatory pro-
cesses and physicochemical polymer properties such as molecular
weight (MW) [5,11–13], particle size [8], charge [14], hydrophobic-
ity [15], shape [16], and chemical functionality [17–20]. These
studies confirm polymer properties can modulate immune func-
tion. Developing a better understanding of these phenomena and
how immunogenicity evolves during degradation could support
rational design of polymers that serve not only as carriers but also
as agents that help direct or tune immune response.
The mechanistic studies above have focused on non-degradable
or slowly-degrading polymers such as polystyrene and PLGA,
respectively. However, vaccines which allow for tunable, rapid
delivery of antigens, adjuvants, or other small molecules offer
new potential for modulating the development of specific immune
characteristics, for example, by rapidly releasing immune-
polarizing drugs during DC activation or T cell expansion. Poly
(beta-amino esters) (PBAEs) are cationic, pH-sensitive polymers
that degrade over hours to days depending on polymer structure
[21,22]. PBAEs have been used in drug delivery, for DNA and RNA
delivery, and as vaccine carriers [23–33]. In the latter case, PBAEs
have been used for DNA vaccination through condensation of
nucleic acids encoding plasmid antigens to promote T cell medi-
ated anti-tumor responses, to drive antibody response, or for siRNA
immunotherapy to preferentially target glioblastoma [34–40].
Although PBAEs are becoming increasingly useful in vaccination
and immunotherapy, little is known about if and how these mate-
rials elicit intrinsic immunostimulatory or inflammatory effects,
and how the rapid degradation of PBAEs or other materials changes
the intrinsic immunogenic properties in cells or tissues.
We hypothesized that PBAEs would exhibit intrinsic immunos-
timulatory effects that change as a function of polymer form (i.e.,
free, particles) and the extent of polymer degradation (MW). To
test this idea, a prototypical PBAE, Poly 1, was synthesized from
a four-carbon diacrylate monomer and a diamine. The ability of
this material to activate DCs and T cells in co-culture and in mice
was then assessed (Fig. 1). Free Poly1 did not activate DCs or drive
synergistic responses during co-treatment with a TLRa. Since the
immune system has evolved to detect particulate materials and
pathogens, we tested if the properties of PBAE particles change
during degradation and if these effects impact intrinsic immunos-
timulatory function. In contrast to free polymer, particles formed
from intact Poly1 using electrostatic condensation to mimic a com-
mon vaccine formulation method exhibited significant intrinsic
immunostimulatory function that decreased with the extent of
polymer degradation. We discovered that these changes corre-
sponded to changing physicochemical properties including
increasingly negative particle charges, increased particle diameter,
and decreased particle concentration. Mechanistic studies using
particles assembled from Poly1 fragments with distinct MWs con-
firmed this trend, revealing that Poly1 differentially activates
immune cells in culture and mice in a manner that is dependent
on both the form of the polymer and the MW (i.e., degree of degra-
dation). These studies confirm the intrinsic immunogenicity of
PBAEs and provide insight into how the evolving properties of
degradable polymers drive immunogenicity in ways that couldsupport design of new vaccine carriers able to adjuvant or modu-
late immune function.2. Materials and methods
2.1. Materials
Monomers for polymer synthesis (1,4-butanediol diacrylate and
4,40-trimethylenedipiperidine) were purchased from Alfa Aesar
(Ward Hill, MA) and Sigma–Aldrich (St. Louis, MO), respectively.
Tetrahydrofuran (THF), diethyl ether, sodium acetate (SA) buffer,
poly(sodium 4-styrenesulfonate) (SPS), and lipopolysaccharide
from Escherichia coli 0111:B4 (LPS) were also purchased from
Sigma–Aldrich. THF used in GPC studies was purchased from
Macron Fine Chemicals (Center Valley, PA). Agilent LS EASICAL
PS-1 polystyrene GPC standards were from Fisher Scientific
(Pittsburgh, PA). Deuterated-chloroform (CDCl3) was bought from
Cambridge Isotope Laboratories (Tewksbury, MA). RPMI-1640
media was purchased from Lonza (Allendale, NJ). Fetal bovine
serum (FBS) was supplied by Corning (Tewksbury, MA). Low MW
polyinosinic-polycytidylic acid (PolyIC) was purchased from
Invivogen (San Diego, CA). CD11c microbeads were purchased from
Miltenyi Biotec (Cambridge, MA). Spleen Dissociation Medium and
CD4 negative selection kits were from STEMCELL Technologies
(Vancouver, British Columbia, Canada). Fluorescent antibody
conjugates were purchased from BD (San Jose, CA) or eBioscience
(San Diego, CA). 5(6)-Carboxyfluorescein diacetate N-
succinimidyl ester (CFSE) was purchased from Sigma–Aldrich.
Evan’s blue dye and 40 lm cell strainers were from VWR (Radnor,
PA).2.2. Cell and animals
Female C57BL6 mice (4–8 weeks, stock #000664) and male C5
7BL/6-Tg(Tcra2D2,Tcrb2D2)1Kuch/J (2D2) mice (10–12 weeks,
stock #006912) were from Jackson Laboratories (Bar Harbor, ME).
The 2D2 strain displays CD4+ T cell receptors transgenic for myelin
oligodendrocyte glycoprotein, residues 35–55 (MOG35–55). All ani-
mals were cared for in compliance with Federal, State, and local
guidelines, and using protocols reviewed and approved by the
University of Maryland’s Institutional Animal Care and Use Com-
mittee (IACUC).2.3. Poly1 synthesis, degradation, and characterization
Poly1 was synthesized via a Michael-type addition reaction as
described previously [21,22,24]. Briefly, 9 mmol of 4,40-trimethyle
nedipiperidine was dissolved in anhydrous THF to form a
500 mg mL1 solution. This solution was added to 9 mmol of 1,4-
butanediol diacrylate and the reaction was heated to 50 C and
stirred for 16 h. The reaction was cooled to room temperature
and the resulting polymer was precipitated in vigorously stirred
ice cold diethyl ether. After collecting the polymer and washing
with additional diethyl ether, the polymer was lyophilized. A
16 mg mL1 solution of Poly1 was prepared in CDCl3 and 1H NMR
was used to confirm the structure. Poly1 was dissolved in THF at
2.5 mg mL1 and a THF-based gel permeation chromatography
(GPC) system (Waters) was used to determine polymer MW com-
pared to polystyrene standards. For degradation studies, Poly1 was
placed in either pH 7 buffer (1 PBS) or pH 5 buffer (100 mM SA)
and incubated at 37 C for increasing intervals to form polymer
fragments. Following incubation, the degraded samples were lyo-
philized and MW (weight average) was determined by GPC.
Fig. 1. Schematic depicting the approach to investigate the intrinsic immunogenicity of Poly1, a degradable, cationic PBAE. DCs, T cells, and mice are treated with free Poly1
or one of two Poly1 particle formulations: (i) particles formed from intact Poly1 then degraded to mimic a common vaccine formulation strategy, or (ii) pools of Poly1
degradation fragments with distinct MWs formed into particles to mechanistically study the link between PBAE properties (e.g., MW, physical form) and DC activation,
antigen presentation, and T cell function.
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Poly1 particles were assembled from either intact polymer then
degraded, or assembled from polymer fragments with distinct
MWs formed by degradation prior to particle assembly. For the for-
mer studies, intact Poly1 was used to prepare particles via electro-
static condensation by mixing 5 mM Poly1 and 20 mM SPS at a
SPS:Poly1 w/w ratio of 1:1.6. These particles were then incubated
at 37 C for specific intervals to determine how degradation of par-
ticles influences the intrinsic immune activity. For mechanistic
studies involving pre-degraded polymer, Poly1 was degraded in
pH 5 buffer for specific intervals to form fractions with distinct
MW fragments of Poly1, then mixed with SPS as above to prepare
particles. For each particle preparation, 400 lg of 5 mM Poly1 was
used to form particles with SPS in pH 5 water while maintaining a
fixed overall volume. Thus the amount of polymer (Poly1, SPS) was
constant in either case, irrespective of whether particles were
formed from intact Poly1 then degraded, or assembled from Poly1
fragments. GPC, as above, was used to quantify the extent of degra-
dation for Poly1 particles formed then degraded. Laser diffraction
(Horiba LA950, Edison, NJ) was used to determine the diameter
of the particles. Zeta potential was determined using a Malvern
Zetasizer Nano ZS90 (Westborough, MA).
2.5. DC activation, antigen presentation, and flow cytometry
Primary CD11c+ DCs were isolated from spleens of C57BL6 mice
via positive selection using the recommended protocols for Spleen
Dissociation Medium (STEMCELL) and CD11c Microbeads
(Miltenyi). Isolated DCs were plated at 100,000 cells per well in a
96 well plate and cultured at 37 C, 5% CO2. DCs were cultured in
RPMI 1640 medium supplemented with 10% FBS, 2 mM
L-glutamine, 1 non-essential amino acids, 10 mM HEPES buffer,1 penicillin and streptomycin, and 55 lM b-mercaptoethanol.
For DC activation studies, DCs were treated with either buffer
(‘‘vehicle”), 10 lg mL1 of TLR3a (PolyIC), 1 lg mL1 of TLR4a
(LPS), 400 ng of Poly1 in free form or in one of two particle formu-
lations: (i) particles assembled from intact Poly1 then degraded, or
(ii) particles assembled from each MW fraction of degraded
polymer. A subset of these formulations was also studied in combi-
nation with the TLRa treatments, as indicated. For all DC studies,
48 h after treatment, cells were stained for viability (DAPI) and
for surface activation markers (i.e., CD40, CD80, CD86, and Major
Histocompatibility Complex II (MHCII)) using fluorescent antibod-
ies conjugates. Cells were examined by flow cytometry (BD CantoII,
San Jose, CA) and data were analyzed using FlowJo v. 10 (TreeStar,
Ashland, OR). For antigen presentation assays, DCs were co-
incubated with 1 lg of a model antigen (SIINFEKL) in soluble form
and each of the polymer formulations indicated and hypothesized
to exhibit an adjuvant effect. After 48 h, cells were stained with
an antibody specific to SIINFEKL presented via MHCI (H-2Kb) then
analyzed by flow cytometry to determine the percentage of DCs
processing and presenting SIINFEKL in MHCI.
2.6. DC/T cell co-culture and T cell proliferation
For studies involving DC and T cell co-cultures, primary DCs
(CD11c+) were isolated from C57BL6 mice as above, and then trea-
ted with Poly1 in free or particle form. A sub-optimal dose (0.05 lg
in 10 lL) of a model antigen (MOG35–55) in soluble form was added
to all wells to serve as the cognate antigen for transgenic 2D2 T
cells. After 48 h in culture, CD4+ T cells were isolated from the
spleens of 2D2 mice using the manufacturer’s recommended pro-
tocol (STEMCELL). Following isolation, T cells were labeled with
CFSE by adding 50 lM of CFSE (in media) per mL of cells, incubated
for 5 min at room temperature, and then washed twice with 10
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added to each well containing DCs, then incubated for 72 h with
50% media replacement every 24 h. After incubation, cells were
collected, and stained with DAPI and antibodies specific to the T
cell surface markers (i.e., CD3e, CD4). Flow cytometry was used
to determine the extent of T cell proliferation via CFSE dilution,
with cells gated beyond the second generation selected as a crite-
rion for proliferated cells.
2.7. i.LN injection of Poly1 into inguinal LNs of mice
For in vivo studies, Poly1 that degraded for 24 h was injected
into the inguinal LNs of mice in free or particle form. In a typical
study, a small region of fur was removed from the lateral hind
quarter of C57BL6 mice by shaving the area and applying a mild
depilatory. The mice were then injected subcutaneously with a tra-
cer dye (Evan’s Blue) on each side of the tail base as previously
reported [41,42]. After allowing time for the tracer dye to drain
to the inguinal LNs for visualization, a 31G insulin needle was used
to inject 10 lL (6.5 lg) of free Poly1, Poly1 particles, or a sham con-
sisting of buffer into each inguinal LN.
2.8. In vivo DC activation, LN cell phenotyping, and lymphadenopathy
24 h after injection, mice were euthanized and the inguinal LNs
were removed and placed in PBS. A single cell suspension was pre-
pared by passing each LN through a 40 lm strainer with PBS and
the total cell number was enumerated using an automated cell
counter (NanoEnTek, Pleasanton, CA). Cells were then stained in
a similar manner to co-culture studies and analyzed by flow
cytometry for viability (DAPI), phenotype (DC, CD11c+; B cell,
B220+; T cell, CD3+), and DC activation markers (i.e., CD40, CD80,
CD86, MHCII).
2.9. Statistical analysis
One way ANOVA with a Tukey post-test was performed using
Graphpad Prism (version 6.02) for statistical testing. A p-value of
0.05 or less was considered significant.
3. Results
3.1. Poly1 degrades to form low MW fragments
Poly1 was synthesized and the reaction product was confirmed
via NMR after 16 h of synthesis (Fig. 2A). Poly1, with a MW of
3.8 kDa (Fig. 2B), was then dissolved in pH 5 buffer. The MW of
Poly1 decreased to 39.9% (1.5 kDA) of the starting MW over
24 h and to 8.4% (0.3 kDa) of the starting MW over one week
(Fig. 2B and C). This degradation rate corresponded to a half-life
of 17.7 h and as previously reported [21], Poly1 degrades to form
byproducts of 1,4-butanediol and bis(b-amino acid). The intrinsic
immunogenicity as polymers degrade to fragments was then stud-
ied in culture and in mice using Poly1 in different forms (i.e., free,
particles) and at different extents of degradation (i.e., MWs).
3.2. Poly1 in free form does not activate DCs
DCs were incubated with Poly1 degradation fragments that
were 100%, 88%, 40%, 20%, or 8% of the starting MW. These frag-
ments were used to treat primary DCs in the absence of antigen
or adjuvants. Following treatment, common DC activation markers
were investigated including: (i) MHCII, a molecule responsible for
presenting antigen to T cells, (ii) CD80 (B7-1) and CD86 (B7-2), cos-
timulatory markers co-expressed with MHC complexes for properT cell activation, and (iii) CD40, a membrane protein expressed on
activated DCs during antigen-specific immunity [43–46]. Com-
pared with control cells treated with buffer (Fig. 3, ‘‘vehicle”), free
Poly1 (Fig. 3, blue) did not increase characteristic DC activation
markers including CD40 (Fig. 3A), CD80 (Fig. 3B), CD86 (Fig. 3C),
and MHCII (Fig. 3D). To test if free Poly1 mediated a synergistic
effect on DC activation in the presence of other adjuvants, DCs
were co-cultured with Poly1 fragments and a TLR3a (PolyIC,
Fig. 3, red) or a TLR4a (LPS, Fig. 3, green). DCs treated with PolyIC
or LPS were strongly activated, but DCs treated with both Poly1
and either TLRa did not exhibit any further increases in activation.
These data indicate that Poly1 in free form does not exhibit strong
intrinsic immunogenicity or cause synergistic effects in the pres-
ence of other adjuvants (i.e., TLR3a, TLR4a).
3.3. Particles assembled from intact Poly1 exhibit the greatest levels of
intrinsic immunogenicity at early stages of degradation
We hypothesized that the form of polymer in solution may
impact the intrinsic immune characteristics of Poly1 by altering
the ability of APCs to detect, internalize, and process Poly1. To test
this idea in a well-controlled manner, particles were formed by
electrostatic condensation of Poly1 with a stable polyanion (SPS).
This approach mimics a common particle synthesis strategy used
in DNA vaccination whereby antigen-encoding plasmid is con-
densed by PBAEs or other cationic polymers or lipids. These parti-
cles were then incubated in buffer at 37 C. GPC results confirmed
that over time, Poly1 in the particles continued to degrade, leading
to a reduction in MW and a lower particle concentration that
resulted in increased optical transmittance (Fig. 4). During this
process, particle size increased, while zeta potential – which was
initially positive (15 mV) – decreased (Fig. 5A and B). Further,
the number of particles decreased to undetectable levels as degra-
dation progressed (Figs. 4C and 5A). Particle size measurements
(volume basis, Fig. S1A) and image analysis (Fig. S1C) at each stage
of degradation revealed that the decreased particle concentration
was due not only to degradation, but also from aggregation of indi-
vidual particles into larger, but fewer, agglomerates. After confirm-
ing SPS had no effect on cell viability (Fig. S2), we screened the
immunogenicity of the Poly1 particles by treating DCs with parti-
cles at each stage of degradation. Poly1 particles at early stages
of degradation strongly activated DCs, then waned as a function
of increasing particle degradation time and decreasing MW
(Fig. 5C–F). These effects were most evident in CD86 and CD80
expression – markers associated with co-stimulation. Thus, parti-
cles formed from Poly1 exhibit intrinsic immunogenicity, and
these effects vary as a function of polymer degradation which
alters the physicochemical properties of these particles. Building
on this discovery, we designed a series of experiments to examine
how the extent of polymer degradation influences particle proper-
ties and immune function in cells and mice.
3.4. Immunogenicity of particles assembled from Poly1 fragments
depends on the extent of degradation
To more directly isolate the role of MW in defining the intrinsic
immunogenicity of PBAEs, we used Poly1 fragments with distinct
MWs as in Fig. 2 to form particles through condensation with
SPS. As observed with particles degraded after formation
(Fig. 4C), the concentration of Poly1 particles formed from distinct
MW fragments generally decreased with degradation time while
transmittance increased. Interestingly, a slight increase in particle
concentration was observed at 4 h (Fig. 6A), and also observed by
microscopy (Fig. S1D). Depending on the degree of degradation,
particles formed using each pool of Poly1 fragments exhibited sizes
of 1.62 lm for intact polymer, increasing to 9.96 lm when
Fig. 2. Poly1 synthesis, characterization, and degradation to low MW polymer chains over one week in buffer. (A) 1H NMR shifts of Poly1 integrated with respect to
deuterated chloroform including chemical shift definitions. (B) GPC chromatograph depicting the change in MW of Poly1 after degradation in pH 5 buffer (100 mM SA).
Increased elution time correlates to lower MW fragments. (C) Poly1 MW changes after incubation in pH 5 and pH 7 (1 PBS) buffers. Data are relative to polystyrene
standards and pooled from three independent experiments for each incubation time. Error bars represent SEM. (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)
Fig. 3. Free Poly1 does not activate DCs. Expression levels of (A) CD40, (B) CD80, (C) CD86, or (D) MHCII on primary CD11c+ DCs treated with free Poly1 degradation fragments
of varying MW. Cells were incubated for 48 h with the indicated Poly1 fragments in the absence (blue) or presence of a TLR3a (PolyIC, red) or TLR4a (LPS, green), respectively.
Expression levels are indicated among DAPI cells and are representative of three similar experiments with samples conducted in triplicate with error bars depicting SEM.
(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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degradation period (Fig. 6B). The zeta potential of particles, which
was positive (15 mV) at early stages, became highly negative as
particles were formed with Poly1 fragments at greater extends of
degradation; particles formed with Poly1 fragments degraded for
one week exhibit values of 9 mV (Fig. 6C). In general, as the
degree of degradation increased, particles exhibited more negativesurface charges, and by the end of the study, a greatly increased
diameter. Compared to the aggregation observed in particles
formed prior to degradation (Fig. S1A and C), particles formed from
pre-degraded Poly1 remained largely free of aggregation until
mostly degraded by 168 h. These results were indicated by particle
size analysis (Fig. S1B) and inspection of microscopy images
(Fig. S1D). We next tested the ability of these particles to activate
Fig. 4. Poly 1 particles degraded for specific intervals following formation exhibit a rapid drop in MW that decreased particle concentration. (A) GPC chromatograph depicting
the change in MW of Poly1 particles after degradation in pH 5 buffer (100 mM SA). Increased elution time correlates to lower MW fragments. (B) The peak corresponding to
the MW distribution of Poly1 changes as particles degrade in pH 5 buffer. (C) Particle concentration and transmittance of particles formed by condensing intact Poly1 prior to
degradation changes with the extent of degradation. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this
article.)
Fig. 5. Pre-formed particles exhibit intrinsic characteristics that activate DCs during early stages of particle degradation. (A) Particle size and (B) zeta potential shift as a
function of degradation time. ‘‘Too dilute” designates formulations for which size measurements could not be reliably obtained due to insufficient particle concentration at
long degradation times. Expression of (C) CD86, (D) CD80, (E) CD40, or (F) MHCII after treatment of CD11c+ DCs with 400 ng of Poly1 particles at varying extents of
degradation. Data correspond to samples prepared in triplicate with error bars representing SEM. For panel B, error bars are smaller than the data markers. (For interpretation
of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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when prepared using intact Poly1 or Poly1 fragments from short
degradation times (i.e., high MW) (Fig. 6D–G). These effects then
decreased as a function of polymer degradation time, with near-baseline activation levels by the end of the study. Interestingly,
CD80 and CD86 levels were elevated with Poly1 fragments
degraded to 40% of the original MW, an observation that correlated
with a transiently-elevated particle concentration at this point.
Fig. 6. Poly1 particles formed with pre-degraded Poly1 fragments induce MW-dependent activation of DCs. (A) Particle concentration and transmittance of particles formed
by condensing Poly1 fragments generated by degradation in buffer prior to condensation. (B) Particle size and (C) zeta potential of Poly1 particles alters with the extent of
degradation. Expression levels of (D) MHCII, (E) CD40, (F) CD80, or (G) CD86 following treatment of primary CD11c+ DCs with 400 ng of Poly1 particles at different extents of
degradation. Vehicle and TLR4a indicate cells treated with buffer or LPS, respectively. Analysis was conducted 48 h after treatment. Expression levels are indicated among
DAPI cells (i.e., live cells). Data are representative of three similar experiments with samples prepared in triplicate. Error bars represent SEM. For panel C, error bars are
smaller than the data markers. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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MHCII, and drive T cell expansion
To test if Poly1-induced DC activation impacts antigen presen-
tation, DCs were treated with a model antigen (SIINFEKL) and
either free Poly1 or particles formed from each MW pool of Poly1
fragments. SIINFEKL presented by these cells in MHCI (H-2Kb)
was then quantified by flow cytometry. While free Poly1 (Fig. 7A,
blue) did not cause a significant increase in antigen presentation
compared to controls (Fig. 7A, gray), DCs treated with Poly1 parti-
cles (Fig. 7A, red) caused a dramatic increase in SIINFEKL presenta-
tion. In agreement with DC activation data (Fig. 6D–G),
presentation levels depended on the extent of degradation, with
the highest levels associated with Poly1 degraded for short times
(i.e., higher MWs) (Fig. 7A). These results indicate that Poly1 parti-
cles stimulate DCs in a manner that enhances the ability of DCs to
effectively present antigen via the MHCI pathway – an arm of
adaptive immunity important in response to viral infection.
To determine if DC activation and antigen presentation induced
by Poly1 particles drives T cell expansion, CD11c+ DCs from C57BL6
mice were co-cultured with CD4+ transgenic T cells from 2D2 mice.
T cells from 2D2 mice display T cell receptors specific for a well-
defined cognate antigen (MOG35–55). In these studies, DCs were
cultured for 48 h with MOG35–55 and either free Poly1, Poly1 parti-
cles formed with pre-degraded Poly1, LPS, or buffer. Freshly iso-
lated CD4+ 2D2 T cells labeled with CFSE were then added to theculture for 72 h. Fig. 7B depicts representative flow cytometry
traces of CFSE dilutions (among DAPI/CD3+/CD4+ cells) for each
treatment group. Samples treated with vehicle and MOG35-55 or
positive controls (i.e., LPS with MOG35–55), caused 8.26% (Fig. 7B,
light gray) and 36.3% (Fig. 7B, dark gray) of T cells to proliferate
beyond the second generation (Fig. 7B, left gates), respectively.
Consistent with DC activation and antigen presentation studies
(Figs. 6 and 7A), cultures treated with free Poly1 (Fig. 7B, blue)
did not exhibit differences in T cell proliferation compared to the
vehicle control (Fig. 7B, gray). Intriguingly, cells treated with Poly1
particles (Fig. 7B, red) induced strong T cell proliferation, resulting
in three distinct generations beyond the second generation. This
expansion was comparable to that observed in co-cultures treated
with a strong TLR3a or TLR4a (i.e., PolyIC, LPS, respectively) and
much greater than the negligible expansion observed in vehicle-
treated cultures (Fig. 7B–D). Compared with free Poly1, Poly1 par-
ticles caused significantly more proliferation as reflected in both
MFI analysis (Fig. 7C) and as a percentage of proliferated cells for
each formulation (Fig. 7D). The effect of Poly1 particles on prolifer-
ation was also weakly influenced by the extent of degradation (i.e.,
MW), with proliferation generally decreasing at lower MWs
(Fig. 7C and D). However, the statistical power of these trends were
weak. Thus, Poly1 particles induce DC activation and antigen pre-
sentation that drives antigen-specific T cell expansion in a manner
that is at least partially dependent on the extent of polymer
degradation.
Fig. 7. Poly1 particles increase MHCI-mediated antigen presentation and antigen-specific T cell proliferation. (A) MFI of signal pertaining to SIINFEKL presented in MHCI
following treatment of DCs with no SIINFEKL (‘‘Untreated”, gray), buffer with SIINFEKL (‘‘SIIN Only”, gray), free Poly1 with SIINFEKL (blue), or Poly1 particles with SIINFEKL
(red) and gated under DAPI cells. 48 h after treatment of DCs as in (A) but using 0.25 lg mL1 of MOG35–55, CD4+ cells isolated from 2D2 mice were added to the wells and
incubated for 72 h. (B) Representative flow cytometry traces showing CFSE dilutions after treatment with MOG35–55 and either buffer (‘‘MOG Only”, gray), TLR4a LPS (‘‘TLR4”,
black), free Poly1 (‘‘Free”, blue), or Poly1 particles formed (‘‘Particles”, red). (C) MFI of CFSE signal among DAPI/CD3+/CD4+ cells following treatments as in (B). (D) Percentage
of DAPI/CD3+/CD4+ cells proliferated beyond the 2nd generation following treatment as in (B) as determined by CFSE dilution. Samples were prepared in triplicate and errors
bars represent SEM. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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To study the effect of Poly1 on secondary lymphoid organs and
local immune function in vivo, we used a technique we recently
established for direct, intra-lymphatic injection to LNs [41,42]. In
these studies, vehicle (i.e., buffer), free Poly1, or Poly1 particles
were introduced to the inguinal LNs of mice. After 24 h, mice were
euthanized and LNs were collected. Following treatment, the per-
centage of CD11c+ DCs found in the LNs treated with vehicle, free
Poly1, or Poly1 particles (Fig. 8A) did not significantly change,
regardless of treatment. Next, we assessed the impact of Poly1
treatment on the activation of LN-resident cells by measuring
expression of CD40 (Fig. 8B), CD80 (Fig. 8C), CD86 (Fig. 8D), and
MHCII (Fig. 8E). Treatment with free Poly1 (Fig. 8, blue) did not
alter activation compared with the vehicle injection control
(Fig. 8, gray). In contrast, Poly1 particles (Fig. 8, red) caused a sig-
nificant increase in the percentage of cells expressing each marker
compared to vehicle or to free Poly1 treatments. In line with the
results of the DC activation studies, treatment with Poly1 particles
(Fig. 8F, red) also increased the total number of cells compared to
treatments with vehicle (Fig. 8F, gray) or free Poly1 (Fig. 8F, blue).
No significant differences were observed in the relative levels of B
and T lymphocytes (Fig. 8G and H) between each group, although
treatment with Poly1 particles appeared to cause a modest
increase in T cells and a corresponding decrease in B cells. These
results indicate that Poly1 exhibits intrinsic immunogenicity both
in primary immune cells and in animals.4. Discussion
In vaccination and immunotherapy, biomaterials offer the abil-
ity to control the delivery kinetics of immune signals; however,
how the intrinsic immunogenicity of synthetic carriers change as
these materials degrade is an area that is not well studied. Several
recent studies demonstrate the intrinsic effects of polymer chem-
istry and physicochemical properties. For example, the Rotello
group investigated the effect of specific chemical groups on inflam-
matory cytokine production using well-controlled chemistry to dis-
play these moieties on stable, gold nanoparticles [15]. Here, we
have carried out mechanistic studies to test if the changing proper-
ties of polymer particles during degradation alters DC activation,
processing and presentation of antigen through MHC-I and MHC-
II pathways, expansion of antigen-specific T cells, and immuno-
genicity in mice. To explore these possibilities, we used PBAEs as
a rapidly-degradable carrier platform. Since PBAEs are commonly
used to condense nucleic acids for gene therapy or DNA vaccination,
we formed particles by electrostatic condensation to mimic this
polymer-enable vaccination strategy [34–40]. This approach also
eliminated stabilizers, surfactants, or other complex compositions
required for nanoparticle and microparticle vaccines synthesized
by methods such as emulsion/phase inversion. These additional
components could hinder isolation of the immunogenic effects of
PBAEs and the change in these characteristics during degradation.
Our primary findings in this study are (i) that PBAEs exhibit
intrinsic immunogenicity, and (ii) that the extent of this activity
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studies with low MW fragments of polymers such as hyaluronic
acid indicate that these materials - which were 4–14 oligosaccha-
rides in size (1500–5300 Da) - induce DC activation, cytokine
secretion, and T cell proliferation, while high MW hyaluronic acid
(80,000–1,000,000 Da) does not [11,12]. In contrast, our studies
with free PBAEs reveal that free Poly1 does not activate DCs
(Fig. 3). This observation may result from the inability of DCs to
efficiently internalize the soluble/relatively low MWs that both
intact and degrading Poly1 exhibit. Although DCs use pinocytosis
to internalize smaller antigens, DCs are able to sample larger, par-
ticulate antigens more efficiently through phagocytosis [47].
Unlike free Poly1, particles formed from intact Poly1 were
immunogenic, exhibiting the greatest activity at early stages of
degradation, with diminishing intrinsic function at longer times.
Poly1 MW became significantly lower at these longer intervals,
while the charge became negative, particle size became much lar-
ger, and particle concentration decreased (Figs. 4 and 5A and B).
Thus, a likely explanation for the decreasing immunogenicity in
Fig. 5C–F observed with increased degradation time is (i) the
reduced number of particles to interact with immune cells, (ii)
the negative surface charge that could hinder association with neg-
atively charged cell membranes [48], and (iii) large particle sizes
that limits the efficiency of endocytosis.
Our findings that Poly1 particles formed from intact Poly1 exhi-
bit changing immunogenicity as Poly1 degrades motivated mecha-
nistic studies to investigate more directly how Poly1 fragments
alter the properties – and resulting immunogenicity – of particles.
Thus we prepared particles from pools of Poly1 fragments with dis-
tinct MW ranges. As with our studies involving particles degraded
after formation from intact Poly1 (Fig. 5), we discovered that par-
ticle size increased inversely with the MW of the Poly1 fragmentsFig. 8. Poly1 particles induce DC activation and lymphadenopathy without altering cell
levels of DC activation markers (B) CD40, (C) CD80, (D) CD86, and (E) MHCII following
original of MW) free Poly1 (‘‘Free”, blue), or Poly1 particles (‘‘Particle”, red). (F) Lymphade
(H) in the LN following treatment as in (A–E). Data are representative of measurem
***p < 0.001). (For interpretation of the references to colour in this figure legend, the reaused for assembly, and zeta potential became increasingly more
negative with increased degradation time (Fig. 6). In general, the
trends in DC activation were also similar (Fig. 6D–G), with greater
activation at lower extents of degradation where particle size was
low (2 lm) and zeta potential was less negative. When Poly1 par-
ticles were formed from smaller MW fragments to mimic longer
degradation times, particles became larger (Fig. 6B) and surface
charge shifted from positive to neutral or slightly negative
(Fig. 6C). However, we also observed a transient elevation in acti-
vation with particles formed from fragments 40% of the starting
MW, though the statistical power of this trend was weak. Our
observation of this effect underscores an important role for particle
concentration, as the properties of particles formed with these
fragments resulted in an increased concentration of particles
(Figs. 6A and S2D) for the same polymer mass used for the other
fragment pools. Together, these data suggest several conclusions.
First, activation is high when particles are at an easily-
internalized size (e.g., one to several microns), but before exhibit-
ing a strong negative surface charge that could hinder electrostatic
association with negatively charged cell membranes. As degrada-
tion continues to greater extents (e.g., 8% of starting MW), particle
diameters reach sizes that may be too large to internalize and exhi-
bit negative surfaces. Second, since the Poly1 dose was fixed, par-
ticle concentration changes both because polymer is degrading and
due to aggregation that results in larger, but fewer, particles. These
effects result in particle concentration generally decreasing with
time. The transient increase in concentration – and corresponding
increase in DC activation – observed with the 40% fragments could
result from dispersion of small aggregates (e.g., dimers or trimers)
that may form during initial condensation, but that are separated
as the particles begin to degrade. However, additional studies are
needed to confirm this possibility. In support of the types ofcomposition after i.LN injection. (A) Percentage of CD11c+ DCs in LN and expression
treatment of C57BL6 mice with buffer alone (‘‘Vehicle”, gray), 24 h degraded (40%
nopathy as determined by total cell number and percentage of B cells (G) and T cells
ents of at least four LNs with error bars representing SEM. (*p < 0.05; **p < 0.01;
der is referred to the web version of this article.)
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observed that directly synthesizing PBAEs with different MWs
impacts the size and zeta potential of electrostatically-condensed
PBAE particles, though this study did not investigate the immuno-
genicity of the particles [49]. Together, the two approaches we
used to characterize the impact of MW on the changing immuno-
genicity of Poly1 reveal that these changes are a function, at least
in part, of changes in particle charge, size, and concentration that
result during degradation.
Another interesting result was observed in studying the impact
of Poly1 particle treatment on the presentation of antigen through
MHCI and MHCII. The MHCI pathway is important in promoting
cell-mediated (i.e., CD8+ T cells) responses to destroy cells infected
with intracellular pathogens (i.e., viruses) and in new therapeutics
such as cancer vaccination and immunotherapy. Our studies reveal
an increase in SIINFEKL antigen presentation at low extents of
degradation (Fig. 7A). Using T cells from transgenic mice, we also
discovered that, in general, Poly1 particles cause an adjuvant effect
to promote antigen-specific proliferation through the MHCII path-
way at levels that are comparable to those observed in mice trea-
ted with LPS and the cognate antigen (Fig. 7B–D). Further,
proliferation was not observed when only the antigen was present.
Proliferation was only a weak function of MW, though this may be
expected due to the exponential nature of T cell expansion and the
complexity of the signals playing a role in engaging the T cell
receptor (e.g., DC signals, cytokines/soluble factors, cell–cell con-
tacts). These co-culture studies demonstrate that Poly1 particles
serve as adjuvants by activating DCs to present antigen through
both the MHCI and MHCII pathways, as well as enhancing the
co-stimulatory molecules needed to expand antigen-specific T
cells. These data also highlight the ability of Poly1 – even in the
absence of any other immune cues – to drive functional responses
in a manner that is dependent on the form and degradation state of
the polymer.
In mice, we discovered that Poly1 alters the composition and
function of LNs. Local injection in these studies allowed careful
control over the composition and dose of the materials in LNs,
revealing that Poly1 is immunogenic in vivo and that the level of
this activity depends on the material properties (Fig. 8). Treatment
with Poly1 particles led to an increase in the number of cells in LNs
and activated DCs, while the effects of free Poly1 on LN-resident
cells were more modest. Together, these observations suggest that
the intrinsic immunogenicity of Poly1 promotes a general (innate)
stimulatory effect, with only a weak polarization of the T or B cell
compartment. However, these analyses were carried out after 24 h;
at later time points and in future studies when antigen and adju-
vant are present, antigen-specific effects may be observed. Sup-
porting this possibility, a small biasing toward the T cell
compartment was observed in LNs after treatment with Poly1 par-
ticles, slightly increasing the frequency of T cells (Fig. 8H) and
slightly decreasing the frequency of B cells (Fig. 8G).
The ‘‘danger model” describes the evolution of immune path-
ways that function by detecting pathogens through broad struc-
tural features that are uncommon in animals and humans [50].
Some of these characteristics include materials in a particulate
form (e.g., virion particles, bacterial cells), short hydrophobic frag-
ments, and polymers or other repetitive structures such as the
polysaccharides that commonly comprise bacterial membranes.
In our studies, when Poly1 particles were at an optimal size for
internalization and positive or neutral, activation was greatest.
These effects correlated to other functions such as antigen presen-
tation and proliferation. However at low MWs, activation dimin-
ished. Thus, in line with the danger model, our results suggest
that broad physicochemical features (e.g., size, charge) – as well
as direct effects from changing MW and number of repeat units
– account for the evolving immunostimulatory properties of Poly1.5. Conclusion
Previous studies have confirmed the intrinsic immunogenicity
of several biomaterials important in the delivery of drugs, vaccines,
and immunotherapies. However, these studies have not focused on
how this activity may evolve as materials degrade, and have not
been carried out using rapidly-degradable polymer classes such
as PBAEs. Here, we have demonstrated that PBAEs, an important
polymer class in recent drug delivery and vaccine studies, exhibit
strong intrinsic immune effects in a particle form, but not in a free
form. Our results also indicate that these effects depend on the
extent of polymer degradation, and at least in part, occur because
the degrading polymer impacts particle properties such as size,
charge, and concentration. Future studies involving treatment of
mice with PBAEs at differing extents or rates of degradation will
reveal how these materials impact LN structure and function with
respect to polymer properties. This approach could also provide
new knowledge of how the intrinsic immunogenicity observed
here or with other polymers translates to polarization of functional
immune outcomes when antigens or other adjuvants are present.
Ultimately, this knowledge could contribute to the design of
polymers that allow better control over the types, durations, and
magnitudes of responses generated with new vaccines or
immunotherapies.Disclosure
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